Last reviewed · How we verify
Pliaglis
At a glance
| Generic name | Pliaglis |
|---|---|
| Also known as | lidocaine and tetracaine |
| Sponsor | University of Michigan |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children (NA)
- Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults (PHASE3)
- Fractional Laser Drug Delivery of a Local Anesthetic (NA)
- A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice
- Evaluate Efficacy, Safety & Subject Satisfaction of Pain Management With Pliaglis® Cream for Dermal Filler Injections (PHASE4)
- Synera Venipuncture Pain (PHASE2)
- The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children (PHASE2)
- Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pliaglis CI brief — competitive landscape report
- Pliaglis updates RSS · CI watch RSS
- University of Michigan portfolio CI